Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Saved in:
| Title: | Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. |
|---|---|
| Authors: | Kersting S; Department of Hematology, HAGA Teaching Hospital, The Hague, Netherlands. Electronic address: s.kersting@hagaziekenhuis.nl., Dubois J; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands., Nasserinejad K; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Dobber JA; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Mellink C; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, Netherlands., van der Kevie-Kersemaekers AF; Department of Human Genetics, Section Cytogenetics, Amsterdam University Medical Center, Amsterdam, Netherlands., Evers LM; Department of Laboratory Special Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., de Boer F; Department of Internal Medicine, Ikazia Hospital, Rotterdam, Netherlands., Koene HR; Department of Hematology, Antonius Hospital, Nieuwegein, Netherlands., Schreurs J; Department of Internal Medicine, Martini Hospital, Groningen, Netherlands., van der Klift M; Department of Internal Medicine, Amphia Hospital, Breda, Netherlands., Velders GA; Department of Internal Medicine, Gelderland Valley Hospital, Ede, Netherlands., van der Spek E; Department of Internal Medicine, Rijnstate Hospital, Arnhem, Netherlands., van der Straaten HM; Department of Internal Medicine, St Jansdal Hospital, Harderwijk, Netherlands., Hoogendoorn M; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, Netherlands., van Gelder M; Department of Hematology, MUMC, Maastricht, Netherlands., Posthuma EFM; Department of Internal Medicine, RDGG, Delft, Netherlands., Visser HPJ; Department of Internal Medicine, Northwest Clinics, Alkmaar, Netherlands., Houtenbos I; Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, Netherlands., Idink CAM; Department of Internal Medicine, ZorgSaam hospital, Terneuzen, Netherlands., Issa DE; Department of Internal Medicine, Jeroen Bosch hospital, 's-Hertogenbosch, Netherlands., Dompeling EC; Department of Hematology, Isala Hospital, Zwolle, Netherlands., van Zaanen HCT; Department of Internal Medicine, St Franciscus Hospital, Rotterdam, Netherlands., Veelken H; Department of Hematology, LUMC, Leiden, Netherlands., Levenga H; Department of Internal Medicine, Groene Harthospital, Gouda, Netherlands., Tick LW; Department of Internal Medicine, Maxima MC, Eindhoven, Netherlands., Terpstra WE; Department of Internal Medicine, OLVG, Amsterdam, Netherlands., Tonino SH; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands., Boyer M; Roche Products Limited, Welwyn Garden City, UK., Mobasher M; Genentech, South San Francisco, CA, USA., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands., Kater AP; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands. |
| Corporate Authors: | HOVON CLL study group |
| Source: | The Lancet. Haematology [Lancet Haematol] 2022 Mar; Vol. 9 (3), pp. e190-e199. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
